Nadofaragene firadenovec is an adenovirus-based gene therapy that has shown promise in phase 1 and 2 trials for high-grade non-muscle invasive bladder cancer (NMIBC) that is refractory to Bacillus Calmette-Guérin (BCG) treatment.
A single-arm phase 3 trial subsequently investigated the safety and efficacy nadofaragene firadenovec in 157 BCG-unresponsive NMIBC patients. Presented at ASCO GU 2020 by Dr Stephen Boorjian, the results showed that the gene therapy is able to elicit durable responses.